Bank of New York Mellon’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43.9M | Buy |
358,300
+16,835
| +5% | +$1.76M | 0.01% | 1146 |
|
|
2026
Q1 | $36M | Sell |
341,465
-8,923
| -3% | -$790K | 0.01% | 1197 |
|
|
2025
Q4 | $30.6M | Sell |
350,388
-12,873
| -4% | -$1.05M | 0.01% | 1292 |
|
|
2025
Q3 | $24.1M | Sell |
363,261
-24,821
| -6% | -$1.41M | ﹤0.01% | 1441 |
|
|
2025
Q2 | $21.4M | Buy |
388,082
+11,219
| +3% | +$538K | ﹤0.01% | 1474 |
|
|
2025
Q1 | $18.2M | Sell |
376,863
-13,925
| -4% | -$584K | ﹤0.01% | 1550 |
|
|
2024
Q4 | $15.1M | Buy |
390,788
+34,455
| +10% | +$1.5M | ﹤0.01% | 1719 |
|
|
2024
Q3 | $16M | Buy |
356,333
+152,034
| +74% | +$6.14M | ﹤0.01% | 1698 |
|
|
2024
Q2 | $7.08M | Buy |
204,299
+17,065
| +9% | +$500K | ﹤0.01% | 2148 |
|
|
2024
Q1 | $5.42M | Sell |
187,234
-15,943
| -8% | -$434K | ﹤0.01% | 2284 |
|
|
2023
Q4 | $4.66M | Buy |
203,177
+1,733
| +0.9% | +$30.3K | ﹤0.01% | 2399 |
|
|
2023
Q3 | $3.36M | Buy |
201,444
+1,869
| +0.9% | +$36.3K | ﹤0.01% | 2532 |
|
|
2023
Q2 | $5.51M | Buy |
199,575
+31,042
| +18% | +$777K | ﹤0.01% | 2269 |
|
|
2023
Q1 | $3.88M | Buy |
168,533
+4,208
| +3% | +$70.7K | ﹤0.01% | 2440 |
|
|
2022
Q4 | $1.79M | Buy |
164,325
+6,266
| +4% | +$52.9K | ﹤0.01% | 2911 |
|
|
2022
Q3 | $1.33M | Buy |
158,059
+15,988
| +11% | +$151K | ﹤0.01% | 3067 |
|
|
2022
Q2 | $1.12M | Buy |
142,071
+2,302
| +2% | +$27.8K | ﹤0.01% | 3159 |
|
|
2022
Q1 | $3.31M | Buy |
139,769
+1,275
| +0.9% | +$35.9K | ﹤0.01% | 2651 |
|
|
2021
Q4 | $4.74M | Buy |
138,494
+7,361
| +6% | +$233K | ﹤0.01% | 2492 |
|
|
2021
Q3 | $2.32M | Sell |
131,133
-15,197
| -10% | -$648K | ﹤0.01% | 2897 |
|
|
2021
Q2 | $6.57M | Buy |
146,330
+12,735
| +10% | +$420K | ﹤0.01% | 2368 |
|
|
2021
Q1 | $3.46M | Buy |
133,595
+4,291
| +3% | +$109K | ﹤0.01% | 2629 |
|
|
2020
Q4 | $2.61M | Buy |
129,304
+34,850
| +37% | +$750K | ﹤0.01% | 2685 |
|
|
2020
Q3 | $1.85M | Sell |
94,454
-6,898
| -7% | -$129K | ﹤0.01% | 2714 |
|
|
2020
Q2 | $1.79M | Buy |
101,352
+17,769
| +21% | +$223K | ﹤0.01% | 2747 |
|
|
2020
Q1 | $590K | Buy |
83,583
+1
| +0% | +$7 | ﹤0.01% | 3272 |
|
|
2019
Q4 | $589K | Buy |
83,582
+6,180
| +8% | +$61.4K | ﹤0.01% | 3509 |
|
|
2019
Q3 | $930K | Sell |
77,402
-26,686
| -26% | -$336K | ﹤0.01% | 3216 |
|
|
2019
Q2 | $1.26M | Buy |
104,088
+41,052
| +65% | +$454K | ﹤0.01% | 3069 |
|
|
2019
Q1 | $792K | Sell |
63,036
-233
| -0.4% | -$2.06K | ﹤0.01% | 3316 |
|
|
2018
Q4 | $426K | Hold |
63,269
| – | – | ﹤0.01% | 3569 |
|
|
2018
Q3 | $651K | Hold |
63,269
| – | – | ﹤0.01% | 3508 |
|
|
2018
Q2 | $426K | Buy |
63,269
+13,303
| +27% | +$102K | ﹤0.01% | 3697 |
|
|
2018
Q1 | $430K | Buy |
49,966
+5,493
| +12% | +$103K | ﹤0.01% | 3647 |
|
|
2017
Q4 | $925K | Buy |
44,473
+15,412
| +53% | +$273K | ﹤0.01% | 3296 |
|
|
2017
Q3 | $513K | Buy |
29,061
+1,435
| +5% | +$19.9K | ﹤0.01% | 3578 |
|
|
2017
Q2 | $313K | Buy |
27,626
+1,478
| +6% | +$15.8K | ﹤0.01% | 3802 |
|
|
2017
Q1 | $335K | Buy |
26,148
+3,433
| +15% | +$55.3K | ﹤0.01% | 3713 |
|
|
2016
Q4 | $500K | Buy |
22,715
+8,513
| +60% | +$190K | ﹤0.01% | 3595 |
|
|
2016
Q3 | $301K | Buy |
+14,202
| New | +$194K | ﹤0.01% | 3759 |
|
Other funds holding PTGX
JJ
N
Bank of New York Mellon's PTGX Position: Q2 2026 in Review
Bank of New York Mellon increased its Protagonist Therapeutics (PTGX) stake by 4.9% in Q2 2026, buying an estimated $1.76M and bringing the position to 358,300 shares worth $43.9M. The position accounts for 0.01% of the portfolio, ranked #1146.
Bank of New York Mellon first reported a position in PTGX in Q3 2016 and has held it in 40 quarters since. 195 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.
- Bank of New York Mellon held 358,300 shares of Protagonist Therapeutics worth $43.9M as of Q2 2026.
- Bank of New York Mellon bought 16,835 Protagonist Therapeutics shares in Q2 2026, an estimated $1.76M.
- Protagonist Therapeutics made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1146 holding.
- Bank of New York Mellon first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 40 quarters since.
- 195 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.